Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science.

Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. Abstract Text:

PURPOSE OF REVIEW: Intestinal fibrosis is a potentially serious complication of inflammatory bowel disease and its pathophysiology is still unclear. This review will discuss recent developments relating to sources of fibroblasts in intestinal inflammation, mediators that modulate fibroblast activation and function, as well as new clinical, laboratory, endoscopic and radiological studies aimed at improving diagnosis and management of intestinal fibrosis in inflammatory bowel disease. RECENT FINDINGS: The fibroblast remains the central cell responsible for intestinal fibrosis in inflammatory bowel disease and transforming growth factor-beta1 is still the most potent pro-fibrogenic cytokine. Novel mediators, however, are being identified that modulate fibroblast function, such as interleukin-13, interleukin-21, galectin-3, osteopontin, Wnt and toll-like receptor ligands, and anti-tumor necrosis factor-alpha agents. New fibroblast sources are being identified, such as fibrocytes, and new mechanisms of fibroblast generation, like epithelial- and endothelial-to-mesenchymal transition. Animal models of intestinal fibrosis are still few, but new ways to induce gut fibrosis are being explored. Serological markers indicating a clinically complicated course that includes intestinal fibrosis are promising and are being tested in adult and pediatric populations, particularly in Crohn's disease. Video capsule endoscopy, the Given Patency capsule, double balloon enteroscopy, and computed tomographic enteroscopy are some of the new modalities being developed to assess the risk and improve the diagnosis of intestinal fibrosis. Novel therapeutic approaches include endoscopic balloon dilatation with conventional and double balloon enteroscopy, and local injection of glucocorticoids and tumor necrosis factor-alpha blockers, showing partial but encouraging success. SUMMARY: More studies are needed to improve knowledge of the pathophysiology of intestinal fibrosis if better preventive, diagnostic and therapeutic measures are to be expected in the near future.

Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Current opinion in gastroenterology

VOLUME: 24

Page Numbers: 462-8

Journal Abbreviation: Curr. Opin. Gastroenterol.

ISSN: 1531-7056

DAY: 14

MONTH: Jul

YEAR: 2008

Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 8506887

Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science.

AFFILIATION: Department of Internal Medicine I, University of Regensburg, Regensburg, Germany.

Country: United States

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Curr Opin Gastroenterol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science Related Publications

• Anaphylaxis in the emergency department: a paediatric perspective.
• Angiogenesis blockade as a new therapeutic approach to experimental colitis.
• Gastroesophageal reflux disease-associated esophagitis induces endogenous cytokine production leading to motor abnormalities.
• Immune events associated with inflammatory bowel disease.
• Immune regulation by microvascular endothelial cells: directing innate and adaptive immunity, coagulation, and inflammation.
• Inflammatory bowel disease: progress and current concepts of etiopathogenesis.
• Intestinal fibrosis in inflammatory bowel disease: progress in basic and clinical science.
• Lymphoid cells of the gastrointestinal tract. Isolation procedures.
• Mucosal T-cell immunoregulation varies in early and late inflammatory bowel disease.
• [Recognizing anaphylaxis in the emergency department]